Tango Therapeutics

Cambridge, United States Founded: 2017 • Age: 9 yrs
Novel cancer drugs are developed using synthetic lethality screening.
Request Access

About Tango Therapeutics

Tango Therapeutics is a company based in Cambridge (United States) founded in 2017.. Tango Therapeutics has raised $165 million across 5 funding rounds from investors including Gilead, Casdin Capital and Boxer Capital. The company has 155 employees as of December 31, 2024. Tango Therapeutics offers products and services including PRMT5 Program and CoREST Program. Tango Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Metabolon and MiRagen, among others.

  • Headquarter Cambridge, United States
  • Employees 155 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Tango Therapeutics, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $42.07 M
    15.17
    as on Dec 31, 2024
  • Net Profit
    $-130.3 M
    -28.07
    as on Dec 31, 2024
  • EBITDA
    $-143.1 M
    -28.04
    as on Dec 31, 2024
  • Total Equity Funding
    $165 M (USD)

    in 5 rounds

  • Latest Funding Round
    $15 M (USD), Post-IPO

    Oct 24, 2025

  • Investors
    Gilead

    & 4 more

  • Employee Count
    155

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Tango Therapeutics

Tango Therapeutics is a publicly listed company on the NASDAQ with ticker symbol TNGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: TNGX . Sector: Health technology · USA

Products & Services of Tango Therapeutics

Tango Therapeutics offers a comprehensive portfolio of products and services, including PRMT5 Program and CoREST Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Targets tumors using synthetic lethality for precision medicine.

Develops targeted therapies for cancer treatment approaches.

People of Tango Therapeutics
Headcount 10-50
Employee Profiles 88
Board Members and Advisors 11
Employee Profiles
People
Adam Crystal
President, Research & Development
People
Laurie Callen
Vice President, Biometrics
People
Maxim Pimkin
Senior Director, Clinical Development
People
Heather Dibenedetto
VP of Development Operations

Unlock access to complete

Board Members and Advisors
people
Antoni Ribas
Scientific Advisor
people
Alexis Borisy
Director
people
Malte Peters
Director
people
William G. Kaelin
Scientific Advisor

Unlock access to complete

Funding Insights of Tango Therapeutics

Tango Therapeutics has successfully raised a total of $165M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Post-IPO — $15.0M
  • First Round

    (30 Mar 2017)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2025 Amount Post-IPO - Tango Therapeutics Valuation

investors

Aug, 2023 Amount Post-IPO - Tango Therapeutics Valuation

investors

Aug, 2020 Amount Series B - Tango Therapeutics Valuation Casdin Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Tango Therapeutics

Tango Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, Casdin Capital and Boxer Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investing in Life Sciences sectors like Healthcare and Biotechnology.
Founded Year Domain Location
Biotech startups are funded by this venture capital firm.
Founded Year Domain Location
Tavistock Group is engaged in global diversified investments.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Tango Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Tango Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Tango Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Tango Therapeutics

Tango Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Metabolon and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
Solutions for biomarker discovery and diagnostic testing are provided.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Tango Therapeutics

When was Tango Therapeutics founded?

Tango Therapeutics was founded in 2017.

Where is Tango Therapeutics located?

Tango Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Who is the current CEO of Tango Therapeutics?

Barbara Weber is the current CEO of Tango Therapeutics.

Is Tango Therapeutics a funded company?

Tango Therapeutics is a funded company, having raised a total of $165M across 5 funding rounds to date. The company's 1st funding round was a Series B of $50M, raised on Mar 30, 2017.

How many employees does Tango Therapeutics have?

As of Dec 31, 2024, the latest employee count at Tango Therapeutics is 155.

What is the annual revenue of Tango Therapeutics?

Annual revenue of Tango Therapeutics is $42.07M as on Dec 31, 2024.

What does Tango Therapeutics do?

Tango Therapeutics was founded in 2017 in Cambridge, United States, as a biotechnology firm focused on oncology. Precision therapies are created by identifying genetic vulnerabilities in tumor suppressor genes through DNA sequencing and CRISPR-based functional screens. Targets are selected for specific patient subgroups, exploiting synthetic lethality to induce tumor cell death while sparing healthy cells. Operations center on early-stage drug discovery in the precision medicine sector.

Who are the top competitors of Tango Therapeutics?

Tango Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does Tango Therapeutics offer?

Tango Therapeutics offers PRMT5 Program and CoREST Program.

Is Tango Therapeutics publicly traded?

Yes, Tango Therapeutics is publicly traded on NASDAQ under the ticker symbol TNGX.

Who are Tango Therapeutics's investors?

Tango Therapeutics has 5 investors. Key investors include Gilead, Casdin Capital, Boxer Capital, Tavistock Group, and Third Rock Ventures.

What is Tango Therapeutics's ticker symbol?

The ticker symbol of Tango Therapeutics is TNGX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available